Literature DB >> 24089556

Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.

Eduardo L V Silveira1, Mark H Fogg, Rachel M Leskowitz, Hildegund C Ertl, Roger W Wiseman, David H O'Connor, Paul Lieberman, Fred Wang, Francois Villinger.   

Abstract

Epstein-Barr virus (EBV) is a vaccine/immunotherapy target due to its association with several human malignancies. EBNA-1 is an EBV protein consistently expressed in all EBV-associated cancers. Herein, EBNA-1-specific T cell epitopes were evaluated after AdC-rhEBNA-1 immunizations in chronically lymphocryptovirus-infected rhesus macaques, an EBV infection model. Preexisting rhEBNA-1-specific responses were augmented in 4/12 animals, and new epitopes were recognized in 5/12 animals after vaccinations. This study demonstrated that EBNA-1-specific T cells can be expanded by vaccination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089556      PMCID: PMC3838282          DOI: 10.1128/JVI.01947-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

Authors:  Yili Yin; Bénédicte Manoury; Robin Fåhraeus
Journal:  Science       Date:  2003-09-05       Impact factor: 47.728

2.  Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Authors:  J Levitskaya; M Coram; V Levitsky; S Imreh; P M Steigerwald-Mullen; G Klein; M G Kurilla; M G Masucci
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

3.  An animal model for acute and persistent Epstein-Barr virus infection.

Authors:  A Moghaddam; M Rosenzweig; D Lee-Parritz; B Annis; R P Johnson; F Wang
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.

Authors:  J J Oudejans; D F Dukers; N M Jiwa; A J van den Brule; F A Grässer; P C de Bruin; A Horstman; W Vos; J van Gorp; J M Middeldorp; C J Meijer
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

5.  Protection against lethal viral infection by vaccination with nonimmunodominant peptides.

Authors:  M Oukka; J C Manuguerra; N Livaditis; S Tourdot; N Riche; I Vergnon; P Cordopatis; K Kosmatopoulos
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

6.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host.

Authors:  Pierre Rivailler; Angela Carville; Amitinder Kaur; Pasupuleti Rao; Carol Quink; Jeffery L Kutok; Susan Westmoreland; Sherry Klumpp; Meredith Simon; Jon C Aster; Fred Wang
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

8.  Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface.

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; Don C Wiley; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.

Authors:  Steven P Lee; Jill M Brooks; Hatim Al-Jarrah; Wendy A Thomas; Tracey A Haigh; Graham S Taylor; Sibille Humme; Aloys Schepers; Wolfgang Hammerschmidt; John L Yates; Alan B Rickinson; Neil W Blake
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

10.  A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome.

Authors:  H Feichtinger; S L Li; E Kaaya; P Putkonen; K Grünewald; K Weyrer; D Böttiger; I Ernberg; A Linde; G Biberfeld
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  2 in total

1.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 2.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.